Sanara MedTech Inc. (SMTI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 16 | 24 | 46 | 65 | 87 | 103 | 110 | 117 |
| Operating profit | $m | 9 | 10 | ||||||
| Net profit | $m | -4 | -8 | -8 | -4 | -10 | -38 | -32 | 2 |
| EPS reported | $ | -4.36 | -3.72 | ||||||
| Operating cashflow per share | $ | 0.79 | 0.66 | ||||||
| Capex per share | $ | 0.54 | 0.14 | ||||||
| FCF per share | $ | 0.25 | 0.52 | ||||||
| Free cash flow | $m | 2 | 5 | ||||||
| Net debt | $m | 30 | 31 | ||||||
| Book value equity | $m | 6 | 8 | ||||||
| Book value per share | $ | 0.69 | 0.92 | ||||||
| Number of shares | m | 8.62 | 8.66 | ||||||
| DPS (TTM paid) | $ | 0.00 | 33.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 33.96 | 25.35 | ||||||
| P/S LTM | x | 1.95 | 1.83 | ||||||
| P/FCF LTM | x | 93.17 | 44.71 | ||||||
| EV/EBITDA LTM | x | 25.80 | 24.63 | ||||||
| EV/Sales LTM | x | 2.26 | 3.16 | ||||||
| Earnings Yield LTM | % | -18.66% | -10.82% | ||||||
| FCF Yield | % | +1.07% | +2.24% | ||||||
| Quality | |||||||||
| ROE | % | -633.46% | -473.55% | ||||||
| ROIC | % | +16.73% | +18.02% | ||||||
| Operating margin | % | +8.87% | +9.36% | ||||||
| Gross margin | % | +90.13% | +91.33% | ||||||
| FCF/Sales | % | +2.10% | +4.10% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +18.97% | +26.70% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.04 | 0.09 | ||||||
| Net Debt/EBITDA | x | 3.50 | 3.50 | ||||||
| EBIT/Net interest | x | 1.35 | 1.42 | ||||||
| Net debt/market cap | % | +23.01% | +14.80% | ||||||
| Net debt/Equity | x | 5.02 | 3.91 | ||||||
| Gross debt/equity | x | 8.13 | 6.11 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free